Hypera (HYPE3) Aandelenoverzicht
Hypera S.A. is een farmaceutisch bedrijf in Brazilië. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 1/6 |
| Financiële gezondheid | 2/6 |
| Dividenden | 4/6 |
Beloningen
Risicoanalyse
HYPE3 Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Hypera S.A. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | R$22.67 |
| 52 Week Hoogtepunt | R$28.87 |
| 52 Week Laag | R$20.66 |
| Bèta | 0 |
| 1 maand verandering | -3.49% |
| 3 maanden verandering | -4.87% |
| 1 Jaar Verandering | -6.32% |
| 3 jaar verandering | -43.87% |
| 5 jaar verandering | -37.05% |
| Verandering sinds IPO | 171.50% |
Recent nieuws en updates
Hypera's (BVMF:HYPE3) Solid Profits Have Weak Fundamentals
Hypera S.A.'s ( BVMF:HYPE3 ) robust earnings report didn't manage to move the market for its stock. We did some...
HYPE3: Index Exit And Higher Margin Outlook Will Support Future Upside
Analysts have slightly reduced their price target on Hypera to reflect updated assumptions on fair value, revenue growth, profit margin and future P/E, while keeping the overall outlook broadly consistent with prior estimates. What's in the News Hypera S.A. removed from the Brazil IBRX 50 Index, which may affect how index-linked funds and some institutional investors are exposed to the stock (Key Developments).Recent updates
Hypera's (BVMF:HYPE3) Solid Profits Have Weak Fundamentals
Hypera S.A.'s ( BVMF:HYPE3 ) robust earnings report didn't manage to move the market for its stock. We did some...HYPE3: Index Exit And Higher Margin Outlook Will Support Future Upside
Analysts have slightly reduced their price target on Hypera to reflect updated assumptions on fair value, revenue growth, profit margin and future P/E, while keeping the overall outlook broadly consistent with prior estimates. What's in the News Hypera S.A. removed from the Brazil IBRX 50 Index, which may affect how index-linked funds and some institutional investors are exposed to the stock (Key Developments).HYPE3: Slight Index Exit And Firm P/E Outlook Will Support Upside
Analysts have nudged their price target for Hypera slightly lower to reflect small adjustments in fair value, discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a modest trim of about R$0.15 per share. What's in the News Hypera S.A. removed from the Brazil IBRX 50 Index, which may affect how some index and benchmark aware investors treat the stock (Key Developments).HYPE3: Future P/E Multiple Expansion Will Support Further Upside Potential
Analysts have slightly increased their price target on Hypera to reflect updated fair value estimates and adjustments to revenue growth, profit margin expectations, and future P/E assumptions. What's in the News Hypera S.A. is scheduled to hold a board meeting on Dec 11, 2025, which may address governance, capital allocation, or operational planning (company event filing).Hypera (BVMF:HYPE3) Takes On Some Risk With Its Use Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...HYPE3: Future P E Expansion Will Support Further Upside Potential
Analysts have slightly raised their price target on Hypera to $30.24 from $30.14, citing modestly stronger revenue growth expectations that more than offset a small downward revision in projected profit margins and a higher implied future P/E multiple. Valuation Changes Fair Value Estimate has risen slightly from R$30.14 to R$30.24 per share, reflecting a modestly higher intrinsic valuation.What You Can Learn From Hypera S.A.'s (BVMF:HYPE3) P/E
When close to half the companies in Brazil have price-to-earnings ratios (or "P/E's") below 9x, you may consider Hypera...HYPE3: Future P/E Expansion Signals Continued Upside Potential
Analysts have increased their price target for Hypera from $29.59 to $30.14, citing revised estimates that reflect a slightly higher discount rate as well as updated projections for revenue growth and profit margin. Valuation Changes Fair Value: Increased slightly from R$29.59 to R$30.14 per share.Hypera's (BVMF:HYPE3) Anemic Earnings Might Be Worse Than You Think
Hypera S.A.'s ( BVMF:HYPE3 ) stock showed strength, with investors undeterred by its weak earnings report. We think...Does Hypera (BVMF:HYPE3) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Hypera S.A. Just Beat EPS By 8.0%: Here's What Analysts Think Will Happen Next
It's been a sad week for Hypera S.A. ( BVMF:HYPE3 ), who've watched their investment drop 10% to R$23.19 in the week...The Price Is Right For Hypera S.A. (BVMF:HYPE3)
With a price-to-earnings (or "P/E") ratio of 21.7x Hypera S.A. ( BVMF:HYPE3 ) may be sending very bearish signals at...Does Hypera (BVMF:HYPE3) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Hypera's (BVMF:HYPE3) Weak Earnings May Only Reveal A Part Of The Whole Picture
Hypera S.A.'s ( BVMF:HYPE3 ) recent weak earnings report didn't cause a big stock movement. However, we believe that...
Product Expansion And Investments In Chronic Treatments Will Strengthen Future Operations
Hypera's working capital focus will improve cash flow, enhancing net margins and financial stability through inventory and operational efficiency enhancements.Why Investors Shouldn't Be Surprised By Hypera S.A.'s (BVMF:HYPE3) P/E
With a median price-to-earnings (or "P/E") ratio of close to 8x in Brazil, you could be forgiven for feeling...More Unpleasant Surprises Could Be In Store For Hypera S.A.'s (BVMF:HYPE3) Shares After Tumbling 27%
To the annoyance of some shareholders, Hypera S.A. ( BVMF:HYPE3 ) shares are down a considerable 27% in the last month...We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Investors Appear Satisfied With Hypera S.A.'s (BVMF:HYPE3) Prospects
There wouldn't be many who think Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 10x is worth a...We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Hypera S.A.'s (BVMF:HYPE3) Popularity With Investors Is Under Threat From Overpricing
It's not a stretch to say that Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 10.9x right now seems...Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Investors in Hypera S.A. ( BVMF:HYPE3 ) had a good week, as its shares rose 3.3% to close at R$34.10 following the...Is Hypera (BVMF:HYPE3) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price
It's not a stretch to say that Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 12.7x right now seems...Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Is Hypera (BVMF:HYPE3) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
It's been a good week for Hypera S.A. ( BVMF:HYPE3 ) shareholders, because the company has just released its latest...Is Hypera (BVMF:HYPE3) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price
Hypera S.A.'s ( BVMF:HYPE3 ) price-to-earnings (or "P/E") ratio of 13x might make it look like a sell right now...Rendement voor aandeelhouders
| HYPE3 | BR Pharmaceuticals | BR Markt | |
|---|---|---|---|
| 7D | -3.0% | -0.2% | -0.7% |
| 1Y | -6.3% | 20.5% | 15.0% |
Rendement versus industrie: HYPE3 presteerde slechter dan de BR Pharmaceuticals -sector, die het afgelopen jaar een rendement van 20.5 % opleverde.
Rendement versus markt: HYPE3 presteerde slechter dan BR Market, dat het afgelopen jaar een rendement van 15 % opleverde.
Prijsvolatiliteit
| HYPE3 volatility | |
|---|---|
| HYPE3 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in BR Market | 8.4% |
| 10% least volatile stocks in BR Market | 1.9% |
Stabiele aandelenkoers: HYPE3 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de BR markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van HYPE3 is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1999 | 10,564 | Breno Pires de Oliveira | www.hypera.com.br |
Hypera S.A. is een farmaceutisch bedrijf in Brazilië. Het biedt producten op recept aan onder de merknamen Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex - A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, en velunid merken. Het bedrijf levert ook zonbeschermende en vochtinbrengende huidverzorgingsproducten onder de merknamen Mantecorp Skincare; soortgelijke producten onder de merknamen Doralgina, Dropy D, Equilibrisse, Balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum en Torsilax; en receptvrije geneesmiddelen onder de merknamen Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil en Neosaldina, evenals soortgelijke en generieke geneesmiddelen onder het merk Neo Química.
Hypera S.A. Samenvatting
| HYPE3 fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | R$15.95b |
| Inkomsten(TTM) | R$1.20b |
| Inkomsten(TTM) | R$7.70b |
Is HYPE3 overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| HYPE3 resultatenrekening (TTM) | |
|---|---|
| Inkomsten | R$7.70b |
| Kosten van inkomsten | R$3.15b |
| Brutowinst | R$4.55b |
| Overige uitgaven | R$3.35b |
| Inkomsten | R$1.20b |
Laatst gerapporteerde inkomsten
Dec 31, 2025
Volgende inkomensdatum
Aug 06, 2026
| Winst per aandeel (EPS) | 1.70 |
| Brutomarge | 59.04% |
| Nettowinstmarge | 15.53% |
| Schuld/Eigen Vermogen Verhouding | 74.6% |
Hoe presteerde HYPE3 op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/21 15:12 |
| Aandelenkoers aan het einde van de dag | 2026/05/20 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Hypera S.A. wordt gevolgd door 22 analisten. 12 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Andréa Aznar | BB Banco de Investimento S.A. |
| Robert Ford Aguilar | BofA Global Research |
| Marcio Osako | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |